2/7/2023  9:39:01 PM Chg. -0.260 Volume Bid9:59:55 PM Ask9:59:55 PM Market Capitalization Dividend Y. P/E Ratio
18.835EUR -1.36% 15,736
Turnover: 299,854.910
18.875Bid Size: 275 19.070Ask Size: 275 646.81 mill.EUR 0.00% -

Business description

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
 

Management board & Supervisory board

CEO
Dr. Jean-Paul Kress
Management board
Sung Lee, Dr. Malte Peters, Dr. Roland Wandeler
Supervisory board
Dr. Marc Cluzel, Dr. George Golumbeski, Krisja Vermeylen, Michael Brosnan, Sharon Curran, Wendy Johnson
 

Company data

Name: MorphoSys AG
Address: Semmelweisstr. 7,D-82152 Martinsried/Planegg
Phone: +49-89-89927-0
Fax: +49-89-89927-222
E-mail: info@morphosys.de
Internet: www.morphosys.de
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 70.60%
IPO date: 3/9/1999

Investor relations

Name: Dr. Julia Neugebauer
IR phone: +49-89-89927-26972
IR Fax: -
IR e-mail: investors@morphosys.com

Company calendar

CW 11 | 3/15/2023 4th Quarter/Annual Report
CW 18 | 5/3/2023 Interim Report 1st Quarter/3 Months
CW 20 | 5/17/2023 General Shareholder Meeting
CW 32 | 8/9/2023 Interim Report 2nd Quarter/6 Months
CW 46 | 11/15/2023 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
70.60%
Baillie Gifford & Co
 
6.23%
Royalty Pharma PLC
 
3.91%
Schroders plc
 
3.03%
Invesco Ltd.
 
3.00%
T. Rowe Price Group, Inc.
 
2.99%
Artisan Partners Asset Management Inc.
 
2.95%
Templeton Funds Trust
 
2.85%
BlackRock, Inc.
 
2.45%
Others
 
2.00%